Valuation : Integrity Applications, Inc.

Market Cap 13.1L 11.27L 10.62L 10L 18.1L 12Cr 18.17L 1.26Cr 48.63L 6.35Cr 49.2L 48.13L 20Cr P/E 2024 *
-
P/E 2025 -0.12x
Enterprise Value -26.27L -22.6L -21.28L -19.39L -36.28L -25Cr -36.43L -2.52Cr -97.49L -13Cr -98.63L -96.49L -40Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
89.82%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 55 14/07/2026
Director of Finance/CFO 66 28/01/2025
Chief Operating Officer - 01/02/2025
Director TitleAgeSince
Director/Board Member 59 27/08/2024
Director/Board Member 56 25/08/2023
Chairman 64 13/02/2024
Change 5-day change 1-year change 3-year change Capi.($)
+15.79%+10.00% - - 13.1L
+0.86%-6.98%-2.73%+11.12% 4.64TCr
+0.17%-0.74%+407.28%+546.58% 4.45TCr
-0.86%-2.60%+35.51%+20.35% 4.23TCr
-0.14%-2.98%-0.04%+82.21% 3.99TCr
0.00%-1.72%+13.42%+42.33% 3.28TCr
-3.44%-2.43% - - 1.71TCr
-0.78%-1.13%+20.74%+116.26% 1.64TCr
+0.70%-3.76%+12.33%+30.49% 1.43TCr
-0.86%-4.60%+76.86%+39.36% 1.33TCr
Average +1.03%-2.88%+70.42%+111.09% 2.97TCr
Weighted average by Cap. -0.32%-3.04%+85.97%+133.03%

Financials

2024 2025
Net sales - -
Net income -2.26Cr -1.94Cr -1.83Cr -1.67Cr -3.12Cr -215.02Cr -3.13Cr -22Cr -8.39Cr -109.54Cr -8.49Cr -8.3Cr -347.04Cr -1.94Cr -1.67Cr -1.57Cr -1.43Cr -2.68Cr -184.49Cr -2.69Cr -19Cr -7.2Cr -94Cr -7.28Cr -7.12Cr -297.76Cr
Net Debt -53.5L -46.04L -43.35L -39.5L -73.9L -51Cr -74.19L -5.14Cr -1.99Cr -26Cr -2.01Cr -1.97Cr -82Cr -39.37L -33.88L -31.9L -29.07L -54.38L -37Cr -54.6L -3.78Cr -1.46Cr -19Cr -1.48Cr -1.45Cr -60Cr
Logo Integrity Applications, Inc.
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Employees
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!